Publications & Presentations

Effect of a chimeric antibody targeting CXCL1 in bladder cancer. AACR Annual Conference Orlando, FL April 2023. Kim N, Furuya H, Murakami K, Rosser CJ.

Bcl-6 as a potential therapeutic target in bladder cancer. Furuya H, Murakami K, Kim N, Rosser CJ. AACR Annual Conference Orlando, FL April 2023. Kim N, Furuya H, Murakami K, Rosser CJ.

Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ. Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. PMID: 30809313; PMCID: PMC6376461. 

CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K. Neoplasia. 2016 Oct;18(10):636-646. doi: 10.1016/j.neo.2016.08.002. Epub 2016 Sep 28. Erratum in: Neoplasia. 2017 Mar;19(3):250-251. PMID: 27690238; PMCID: PMC5043399.

CXCL1 is elevated in the urine of bladder cancer patients. Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H. Springerplus. 2015 Oct 15;4:610. doi: 10.1186/s40064-015-1393-9. PMID: 26543745; PMCID: PMC4628002.

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ. BMC Cancer. 2013 Jul 1;13:322. doi: 10.1186/1471-2407-13-322. PMID: 23815949; PMCID: PMC3708804.

Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ. Pathol Res Pract. 2014 Feb;210(2):74-8. doi: 10.1016/j.prp.2013.08.013. Epub 2013 Oct 28. PMID: 24252309. 

Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ. Lab Invest. 2013 Jul;93(7):768-78. doi: 10.1038/labinvest.2013.71. Epub 2013 Jun 3. PMID: 23732813.